Bone health in advanced prostate cancer: pathophysiology and management strategies
Rana R McKay, Heather Hofflich, Gina Woods, Richard Andres, Azeez Farooki · 2026
Read Bone health in advanced prostate cancer: pathophysiology and management strategies by Rana R McKay, Heather Hofflich, Gina Woods, Richard Andres, Azeez Farooki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13548789.txt.
Description
McKay and colleagues reviewed bone health in advanced prostate cancer and how to protect it within care, in a 2026 narrative review. Hormone therapy that lowers testosterone accelerates bone loss from the moment it starts, and once cancer spreads to bone. happens in the great majority of resistant cases, patients face fractures, spinal cord compression, and other skeletal events that erode quality of life.
McKay recommends assessing every man on hormone deprivation with bone density scanning and a bone-quality score. Giving bone-protective agents to all men with resistant cancer and to high-risk men on hormone therapy. Options include bisphosphonate drugs and denosumab, which blocks a bone-breakdown signal, with monitoring for jaw bone damage and low calcium. Several cancer drugs, including abiraterone, enzalutamide, and radium-223, help bone. The authors supply a test-and-treat algorithm and argue management, though underused, should be standard practice.
Catalog record
| CREATOR | Rana R McKay, Heather Hofflich, Gina Woods, Richard Andres, Azeez Farooki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |